

Table 2. Treatment effectiveness for enthesitis outcomes in randomized controlled trials in psoriatic arthritis.

Study	Agent	No.	Enthesitis Measure	Results (p value vs placebo, at followup)	Effect Size [95%CI]
Clegg 1996 ¹⁵	Sulfasalazine, 2 g qd	221	Modified Mander Enthesitis Index	Mean at baseline (\pm SD)/ mean change (\pm SD) 36 wks. S: $4.3 \pm 5.9/-1.5 \pm 4.5$; P: $4.4 \pm 5.6/-0.9 \pm 4.1$; NS % at baseline/16 wks. I: 25/14. P: 25/31 (p = 0.021)	-0.1 [-0.4, 0.1]
Antoni 2005 ⁸	Infliximab, 5 mg/kg q8w	104	IMPACT Index	% at baseline/14 wks/24 wks. I: 42/22/20; P: 35/34/37; (p = 0.016/p = 0.002)	NA
Antoni 2005 ⁹	Infliximab, 5 mg/kg q8w	200	IMPACT Index	NR/NS	NA
Mease 2005 ¹⁰	Adalimumab, 40 mg q2w	313	IMPACT Index	Mean (\pm SD) at baseline/mean change 16 wks. Ad: $0.9 \pm 1.2/-0.5$; P: $1.0 \pm 1.3/-0.2$; NS % at baseline/14 wks/24 wks. G100: 79/61/50 (NS/p = 0.003); G50: 75/55/49 (p = 0.008/p = 0.002); P: 78/71/69	-0.24 [-0.6, 0.2]
Genovese 2007 ¹¹	Adalimumab, 40 mg q2w	100	IMPACT Index	Mean (\pm SD) at baseline/mean change 24 wks. G100: $6.1 \pm 4.1/-52.4$ (p < 0.001) G50: $5.7 \pm 4.0/-46.1$ (p < 0.001) Gtot: $5.9 \pm 4.1/-49.4$ (p < 0.001); P: $5.0 \pm 4.1/-12.9$	-0.62 [-0.9, -0.4]
Kavanaugh 2009 ^{7,12}	Golimumab, 50 mg q4w; 100 mg q4w	406	PsA modified MASES	% at baseline/12 wks. U: 45/23; P: 46/42; p = 0.0163	NA
Gottlieb 2009 ¹³	Ustekinumab, 90 mg or 63 mg qw for 4 wks	146	IMPACT Index	% at baseline/improved** 12 wk/24 wk. E (biw/qw): 40.4/73.7/80.9; E (qw/qw): 35.9/70.0/81.3; (NR)	NA
Sterry* 2010 ¹⁴	Etanercept, 50 mg biw/qw; 50 mg qw/qw	752	IMPACT Index	% at baseline/24 wks. U90: 75.5/60.8 (p = 0.0002); U45: 69.3/68.6 (p = 0.0179); P: 70.4/81.0	
McInnes 2013 ¹⁶	Ustekinumab, 45 mg q12w; 90 mg q12w	615	PsA modified MASES	Mean (\pm SD) at baseline/mean change 24 wks U90: $5.7 \pm 3.8/-2.5$ (p = 0.002) U45: $5.0 \pm 3.6/-2.0$ (p = 0.057) Utot: $5.4 \pm 3.7/-2.2$ (p = 0.003); P: $5.4 \pm 3.9/-1.3$	-0.31 [-0.5, -0.1]
Ritchlin 2014 ¹⁹	Ustekinumab, 45 mg q12w; 90 mg q12w	312	PsA modified MASES	% at baseline/24 wks U90: 72.4/70.0 (p = 0.01) U45: 69.9/75.7 (p < 0.05); P: 70.2/88.2	-0.19 [-0.4, 0.0]
				Mean (\pm SD) at baseline/mean change 24 wks. U90: $5.7 \pm 3.9/-2.1$ (p = 0.08) U45: $6.5 \pm 3.9/-1.9$ (p = 0.16) Utot: $6.1 \pm 3.9/-2.0$ (p = 0.07); P: $5.5 \pm 4.3/-1.1$	-0.22 [-0.5, 0.1]
Mease 2014 ¹⁷	Certolizumab, 400 mg q4wk; 200 mg q2wk	409	LEI	Mean(\pm SD) at baseline/change (\pm SD) 24 wks. C400: $2.9 \pm 1.6/-1.8 \pm 1.9$ (p = 0.003) C200: $3.1 \pm 1.7/-2.0 \pm 1.8$ (p < 0.001); P: $2.9 \pm 1.6/-1.1 \pm 1.8$	-0.44 [-0.7, -0.2]
Kavanaugh 2014 ¹⁸	Apremilast, 20 mg bid, 30 mg bid	504	MASES	Mean(\pm SD) at baseline/change (\pm SE) 24 wks Ap30: $4.4 \pm 3.1/-1.7 \pm 0.3$ (p = 0.03) Ap20: $5.0 \pm 3.3/-1.6 \pm 0.3$ (NS); P: $5.4 \pm 3.5/-0.8 \pm 0.3$	-0.27 [-0.5, -0.1]

*All studies are double-blind randomized controlled trials (DBRCT) except for Sterry 2010 (2 active arms). **% with improvement in ≥ 1 site. ^p values for comparison of means calculated using the t test. NA: not applicable; NR: not reported; NS: not significant; Ad: adalimumab; Ap: apremilast; C: certolizumab; E: etanercept; G: golimumab; I: infliximab; P: placebo; S: sulfasalazine; U: ustekinumab; bid: twice daily; biw: twice weekly; qd: daily; qw: weekly. Values in bold face are statistically significant.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2014. All rights reserved.